

ICMJE DISCLOSURE FORM

Date: 31/3/2024

Your Name: Liyuan Zhu

Manuscript Title: Intravenous immunoglobulin can induce antibody-dependent cell-mediated cytotoxicity and upregulate FCGR3A and FcγRIIIA expression in vitro

Manuscript number (if known): AOB-23-42

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Fundings: Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010).	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated)	None	

	in item #1 above).		
3	Royalties or licenses	___ None	
4	Consulting fees	___ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Ye Gang, an employee of Zhengzhou RAAS Blood Products Co., Ltd, provided part of the materials and drugs, including IVIG.	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010). The authors also reported receipt of part of the materials and drugs including IVIG from GY.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 31/3/2024

Your Name: Yafei Zhao

Manuscript Title: Intravenous immunoglobulin can induce antibody-dependent cell-mediated cytotoxicity and upregulate FCGR3A and FcγRIIIA expression in vitro

Manuscript number (if known): AOB-23-42

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Fundings: Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010).	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated)	None	

	in item #1 above).		
3	Royalties or licenses	___ None	
4	Consulting fees	___ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Ye Gang, an employee of Zhengzhou RAAS Blood Products Co., Ltd, provided part of the materials and drugs, including IVIG.	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-I-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YF50010). The authors also reported receipt of part of the materials and drugs including IVIG from GY.

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 31/3/2024

Your Name: Gang Ye

Manuscript Title: Intravenous immunoglobulin can induce antibody-dependent cell-mediated cytotoxicity and upregulate FCGR3A and FcγRIIIA expression in vitro

Manuscript number (if known): AOB-23-42

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Fundings: Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010).	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated)	None	

	in item #1 above).		
3	Royalties or licenses	___ None	
4	Consulting fees	___ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Ye Gang, an employee of Zhengzhou RAAS Blood Products Co., Ltd, provided part of the materials and drugs, including IVIG.	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YF50010). The authors also reported receipt of part of the materials and drugs including IVIG from GY. GY serves as an employee of Zhengzhou RAAS Blood Products Co., Ltd.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 31/3/2024

Your Name: Yuwei Huang

Manuscript Title: Intravenous immunoglobulin can induce antibody-dependent cell-mediated cytotoxicity and upregulate FCGR3A and FcγRIIIA expression in vitro

Manuscript number (if known): AOB-23-42

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Fundings: Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010).	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated)	None	

	in item #1 above).		
3	Royalties or licenses	___ None	
4	Consulting fees	___ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Ye Gang, an employee of Zhengzhou RAAS Blood Products Co., Ltd, provided part of the materials and drugs, including IVIG.	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YF50010). The authors also reported receipt of part of the materials and drugs including IVIG from GY.

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 31/3/2024

Your Name: Qing Liu

Manuscript Title: Intravenous immunoglobulin can induce antibody-dependent cell-mediated cytotoxicity and upregulate FCGR3A and FcγRIIIA expression in vitro

Manuscript number (if known): AOB-23-42

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Fundings: Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010).	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated)	None	

	in item #1 above).		
3	Royalties or licenses	___ None	
4	Consulting fees	___ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Gang Ye, an employee of Zhengzhou RAAS Blood Products Co., Ltd, provided part of the materials and drugs, including IVIG.	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YF50010). The authors also reported receipt of part of the materials and drugs including IVIG from GY.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 31/3/2024

Your Name: Peng Jiang

Manuscript Title: Intravenous immunoglobulin can induce antibody-dependent cell-mediated cytotoxicity and upregulate FCGR3A and FcγRIIIA expression in vitro

Manuscript number (if known): AOB-23-42

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Fundings: Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010).	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	___ None	
4	Consulting fees	___ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Ye Gang, an employee of Zhengzhou RAAS Blood Products Co., Ltd, provided part of the materials and drugs, including IVIG.	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YF50010). The authors also reported receipt of part of the materials and drugs including IVIG from GY.

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 31/3/2024

Your Name: Changqing Li

Manuscript Title: Intravenous immunoglobulin can induce antibody-dependent cell-mediated cytotoxicity and upregulate FCGR3A and FcγRIIIA expression in vitro

Manuscript number (if known): AOB-23-42

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Fundings: Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010).	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	___ None	
4	Consulting fees	___ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Ye Gang, an employee of Zhengzhou RAAS Blood Products Co., Ltd, provided part of the materials and drugs, including IVIG.	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YF50010). The authors also reported receipt of part of the materials and drugs including IVIG from GY.

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 31/3/2024

Your Name: Xi Du

Manuscript Title: Intravenous immunoglobulin can induce antibody-dependent cell-mediated cytotoxicity and upregulate FCGR3A and FcγRIIIA expression in vitro

Manuscript number (if known): AOB-23-42

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Fundings: Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010).	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	___ None	
4	Consulting fees	___ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Ye Gang, an employee of Zhengzhou RAAS Blood Products Co., Ltd, provided part of the materials and drugs, including IVIG.	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-I-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YF50010). The authors also reported receipt of part of the materials and drugs including IVIG from GY.

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 31/3/2024
 Your Name: Shengliang Ye
 Manuscript Title: Intravenous immunoglobulin can induce antibody-dependent cell-mediated cytotoxicity and upregulate FCGR3A and FcγRIIIA expression in vitro
 Manuscript number (if known): AOB-23-42

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the **current manuscript only**.

The author’s relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Fundings: Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010).	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	___ None	
4	Consulting fees	___ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Ye Gang, an employee of Zhengzhou RAAS Blood Products Co., Ltd, provided part of the materials and drugs, including IVIG.	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YF50010). The authors also reported receipt of part of the materials and drugs including IVIG from GY.

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 31/3/2024

Your Name: Li Ma

Manuscript Title: Intravenous immunoglobulin can induce antibody-dependent cell-mediated cytotoxicity and upregulate FCGR3A and FcγRIIIA expression in vitro

Manuscript number (if known): AOB-23-42

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Fundings: Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010).	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	___ None	
4	Consulting fees	___ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Ye Gang, an employee of Zhengzhou RAAS Blood Products Co., Ltd, provided part of the materials and drugs, including IVIG.	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YF50010). The authors also reported receipt of part of the materials and drugs including IVIG from GY.

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.